Top Markets
Coin of the day
Alpine Immune Sciences, Inc. Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc.

ALPN
주식 순위 #6581
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company... Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and advancing protein-based immunotherapies. Their therapeutic endeavors address a range of conditions, including various cancers, autoimmune and inflammatory disorders, among others. The company's pipeline features ALPN-101, an ICOS/CD28 antagonist program being developed for autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor aimed at treating cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated inflammatory and autoimmune conditions. Alpine Immune Sciences has established strategic collaborations, including an agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101, and a partnership with Adaptimmune Therapeutics plc to create next-generation SPEAR T cell products. The company was founded in 2007 and operates from its headquarters in Seattle, Washington.
주가
$64.97
마지막 동기화: 2024-05-20
시가총액
$1.97B
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Alpine Immune Sciences, Inc. (ALPN)

카테고리

Alpine Immune Sciences, Inc. (ALPN)의 P/B 비율
August 2026 기준 P/B 비율 TTM: 9.91
Alpine Immune Sciences, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 9.91입니다. 2022년 말 기준 P/B 비율은 1.37였습니다.
Alpine Immune Sciences, Inc.의 P/B 비율 기록 (2012 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
2026 (TTM) 9.91 240.41%
2023 2.91 112.16%
2022 1.37 -53.07%
2021 2.92 -30.87%
2020 4.22 76.50%
2019 2.39 109.27%
2018 1.14 24.25%
2017 0.92 46.95%
2016 0.63 -27.94%
2015 0.87 -110.05%
2014 -8.64 479.51%
2013 -1.49 0.00%
2012 0.00 0.00%
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.3419 -35.98%
US
6.2413 -36.99%
NL
2.5054 -74.71%
AU
3.7087 -62.56%
US
- -
CH